Admin Control Panel

New Post | Settings | Change Layout | Edit HTML | Edit posts | Sign Out
March20 podcast Dr Hazen
anti-TMA pill in a year or 2 ? (scroll 12 mins)

Additional info: https://youtu.be/811v7RLXP9M
MEBO Karen
at UK Findacure conf 2020

Scroll down and select country
MEBO TMAU TESTING DISCONTINUED
(2012-2017)

MEBO Map Testing & Meetups


Full details : https://goo.gl/TMw8xu
want listed ? contact info@meboresearch.org

MEBO - UBIOME study 2018

'PRESS RELEASE'

NCT03582826
ClinicalTrials.gov

MEBO Gut Microbiome Study
"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"
Funded by uBiome Research Grant

"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"

Dynamics of the Gut Microbiota in
Idiopathic Malodor Production
& PATM

Started May 2018 - Ongoing

Current people sent kits : 100/100
3 kits per person

NO LONGER RECRUITING

Participation info : LINK English

MEBO Private Facebook Group
to join : go to
or contact
Join/Watch the weekly
BO Sufferers Podcasts

MEBO TMAU Videos

Petitions

TMAU Petition world
TMAU UK end total:262
TMAU UK ends 23/01/20
TMAU Petition USA end total 204
USA : Moveon open
TMAU (Dominican)
Metabolomic Profiling Study
NCT02683876

Start : Aug 2016
Stage 1 : 27 Canadian volunteers to test
Latest click here (26 oct) :
17 samples returned


Note : Stage 1 is Canada only.
Return cut-off date : passed
Analysis can take 6/8 weeks
Analysis start in/before Nov
MEBO Research is a
EURORDIS and
NORD Member Organization
See RareConnect

Popular Posts (last 30 days)

Upcoming get-togethers


Let us know if you want a meetup listed

Subscribe to Blog

Enter your email address:

Delivered by FeedBurner

You will be sent a verification email

Subscribe in a reader

Blog Archive

MEBO survey for Dr Hazen click here
Read more/less

Regular readers will know that Dr Stan Hazen et al at Cleveland Clinic are developing a TMA-blocker pill, as they proposed in a 2011 paper that TMAO is a factor in CVD. Recently Dr Hazen and colleagues contacted MEBO as they have always thought they could also help with TMAU. This survey is to give them an idea of the 'state of the community'. It is a "version 1". They may not even look (though they have access permission), but it could be useful to give them an overview of the community

MEBO had a zoom call with Dr Hazen and his team in October. Another zoom call is planned when they have time

MEBO Research Clinical Trials

Sunday, November 2, 2008

The Washington Taste & Smell Clinic : A template for a Body Odor & Halitosis Clinic

The history of the Taste and Smell Clinic in Washington is an interesting story, mainly because it could be a blueprint for a Body Odor and Halitosis Research and Treatment Clinic. It is ironic that both problems have to do with smell, and the nice one has a 'home' in society, whereas the 1% or more of body odor and halitosis sufferers who seem to be more in need are 'homeless' in this day and age. Ask anyone with a loss of smell if they would rather have fecal body odor, and vice versa; and compare suicide rates. For obvious reasons, bad luck, and perhaps medical ignorance, it can be deduced how the nice one is recognised by the system whilst the other is still unknown.

Perhaps it was also down to the doctor running the clinic, Dr Henkin, even more than the system. It was originally set up by the NIH in 1969, but through Dr Henkin it later became private and treats patients from throughout the world, possibly because of the unexpected need for such a service. All the right terminology appears in the pages about diagnosis (metabolism, zinc etc). Research papers are published. It sounds like a center of excellence. Basically, the NIH could set up a replica for BO & Halitosis research and treatment using the same model ... and would likely be shocked at the need, especially metabolic odor conditions. Sadly it's a chicken and egg situation.

With the power of the internet, perhaps we can come up with a plan to influence the NIH (petition ? co-ordinated emails ?) to make them aware of the need for a BO & Halitosis clinic, especially for metabolic body odor and/or halitosis, which is obviously 'unrecognised' by the 'system'. But the Clinic could investigate all forms of BO and halitosis.

Perhaps contacting the NIH ORD Undiagnosed disease Program would be a starting point until a plan of action can be put together. As a community we will come up with solutions.


Did you phone the Undiagnosed Diseases Program ?



http://www.tasteandsmell.com/history.htm


The Taste and Smell Clinic is the most successful clinical program in the world devoted to evaluation and treatment of patients with taste and smell dysfunction. Thousands of patients have been treated at The Clinic since its inception. Patients come from all over the world to achieve relief of their various complaints of both loss and distortion of taste and smell. The Taste and Smell Clinic in Washington, D.C. was the first clinical facility in the world established to evaluate and treat patients with dysfunction related to taste and smell. This program was initially set up as part of the clinical research program of the National Heart, Lung and Blood Institute of the NIH in Bethesda, MD. In 1969 it became the clinical arm of the Section on Neuroendocrinology of which Dr. Henkin was the chief. Both inpatients and outpatients were evaluated and treated in this program and studied on a metabolic ward administered by Dr. Henkin. To measure taste and smell function the first systematic tests to measure taste and smell function in patients with these problems were developed and put into practice. To understand the basic mechanisms of taste and smell physiology, systematic, fundamental studies of zinc and copper metabolism in normal volunteers and in patients with a variety of diseases were undertaken and continued for the next 10 years. Through these metabolic studies and use of radioactive and stable zinc isotopes the first basic knowledge of zinc and copper metabolism in patients with taste and smell dysfunction and other clinical disorders including cancer, neurological diseases, endocrine, and metabolic disorders, nutritional and genetic abnormalities of various types was established...

...
With continued growth of the clinical and research programs more space and facilities were required. The Taste and Smell Clinic transferred to the private sector in 1986 while maintaining its relationships with NIH, the Georgetown University Medical Center and recently the George Washington University Medical Center. Because of the move into the private sector a new commercial entity, Sialon, was established to deal with the novel techniques developed at The Taste and Smell Clinic. Many of these technologies been granted US patents and are in the process of being developed by various private companies in the US and abroad. These technologies involve novel modalities to correct various aspects of taste and smell disorders and include treatments for loss and distortion of taste and smell function, disorders of oral cavity sensation including lingual and oral burning, and disorders of perception of local and systemic odors related to body odor.

0 comments:

Post a Comment